Is Archer Aviation a Buy, Sell or Hold?
Vertical takeoff and landing (eVTOL) aircraft sound futuristic but that’s…
Sell
15
BDRX Quote, Financials, Valuation and Earnings
Last price:
$1.55
Seasonality move
:
-25.81%
Day range:
$1.41 - $1.65
52-week range:
$1.14 - $74.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.11x
P/B ratio:
0.09x
Volume:
283.2K
Avg. volume:
2.9M
1-year change:
-94.52%
Market cap:
$942.7K
Revenue:
$474.1K
EPS (TTM):
-$74.60
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -- | -- | $17.97 |
|
ADAP
Adaptimmune Therapeutics PLC
|
$7M | -$0.17 | -92.5% | -8.33% | $1.71 |
|
BCYC
Bicycle Therapeutics PLC
|
$8.7M | -$0.81 | -55.59% | -31.65% | $27.70 |
|
NCNA
NuCana PLC
|
-- | -$0.01 | -- | -99.69% | $104.00 |
|
VRNA
Verona Pharma PLC
|
$53.6M | -$0.03 | -- | -89.84% | $81.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BDRX
Biodexa Pharmaceuticals PLC
|
$1.41 | $17.97 | $942.7K | -- | $0.00 | 0% | 1.11x |
|
ADAP
Adaptimmune Therapeutics PLC
|
$0.23 | $1.71 | $58M | -- | $0.00 | 0% | 0.32x |
|
BCYC
Bicycle Therapeutics PLC
|
$6.38 | $27.70 | $441.5M | -- | $0.00 | 0% | 10.52x |
|
NCNA
NuCana PLC
|
$0.73 | $104.00 | $4.4M | -- | $0.00 | 0% | -- |
|
VRNA
Verona Pharma PLC
|
$54.17 | $81.00 | $4.6B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | 1.825 | -- | 1.20x |
|
ADAP
Adaptimmune Therapeutics PLC
|
80.92% | 4.133 | 36.44% | 2.60x |
|
BCYC
Bicycle Therapeutics PLC
|
-- | 1.224 | -- | 13.61x |
|
NCNA
NuCana PLC
|
-- | 0.371 | -- | -- |
|
VRNA
Verona Pharma PLC
|
37.04% | 0.836 | 3.06% | 10.24x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
ADAP
Adaptimmune Therapeutics PLC
|
-- | -$57.2M | -93.9% | -140.5% | -2197.67% | -$35.4M |
|
BCYC
Bicycle Therapeutics PLC
|
-- | -$67.1M | -25.48% | -26.21% | -1426.21% | -$9.8M |
|
NCNA
NuCana PLC
|
-- | -$1.6M | -- | -- | -- | -$9.3M |
|
VRNA
Verona Pharma PLC
|
$34.6M | -$17.8M | -60.44% | -88.7% | -41.57% | -$29.4M |
Biodexa Pharmaceuticals PLC vs. Competitors
-
Which has Higher Returns BDRX or ADAP?
Adaptimmune Therapeutics PLC has a net margin of -- compared to Biodexa Pharmaceuticals PLC's net margin of -2303.38%. Biodexa Pharmaceuticals PLC's return on equity of -160.77% beat Adaptimmune Therapeutics PLC's return on equity of -140.5%.
Company Gross Margin Earnings Per Share Invested Capital BDRXBiodexa Pharmaceuticals PLC-- -- $6M ADAPAdaptimmune Therapeutics PLC-- -$0.31 $62.1M -
What do Analysts Say About BDRX or ADAP?
Biodexa Pharmaceuticals PLC has a consensus price target of $17.97, signalling upside risk potential of 1183.09%. On the other hand Adaptimmune Therapeutics PLC has an analysts' consensus of $1.71 which suggests that it could grow by 656.32%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Adaptimmune Therapeutics PLC, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Adaptimmune Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings BDRXBiodexa Pharmaceuticals PLC1 0 0 ADAPAdaptimmune Therapeutics PLC2 2 0 -
Is BDRX or ADAP More Risky?
Biodexa Pharmaceuticals PLC has a beta of 1.705, which suggesting that the stock is 70.482% more volatile than S&P 500. In comparison Adaptimmune Therapeutics PLC has a beta of 2.845, suggesting its more volatile than the S&P 500 by 184.488%.
-
Which is a Better Dividend Stock BDRX or ADAP?
Biodexa Pharmaceuticals PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adaptimmune Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biodexa Pharmaceuticals PLC pays -- of its earnings as a dividend. Adaptimmune Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BDRX or ADAP?
Biodexa Pharmaceuticals PLC quarterly revenues are --, which are smaller than Adaptimmune Therapeutics PLC quarterly revenues of $3.2M. Biodexa Pharmaceuticals PLC's net income of -- is lower than Adaptimmune Therapeutics PLC's net income of -$74.2M. Notably, Biodexa Pharmaceuticals PLC's price-to-earnings ratio is -- while Adaptimmune Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biodexa Pharmaceuticals PLC is 1.11x versus 0.32x for Adaptimmune Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDRXBiodexa Pharmaceuticals PLC1.11x -- -- -- ADAPAdaptimmune Therapeutics PLC0.32x -- $3.2M -$74.2M
-
Which has Higher Returns BDRX or BCYC?
Bicycle Therapeutics PLC has a net margin of -- compared to Biodexa Pharmaceuticals PLC's net margin of -1398.44%. Biodexa Pharmaceuticals PLC's return on equity of -160.77% beat Bicycle Therapeutics PLC's return on equity of -26.21%.
Company Gross Margin Earnings Per Share Invested Capital BDRXBiodexa Pharmaceuticals PLC-- -- $6M BCYCBicycle Therapeutics PLC-- -$0.75 $793.1M -
What do Analysts Say About BDRX or BCYC?
Biodexa Pharmaceuticals PLC has a consensus price target of $17.97, signalling upside risk potential of 1183.09%. On the other hand Bicycle Therapeutics PLC has an analysts' consensus of $27.70 which suggests that it could grow by 334.17%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Bicycle Therapeutics PLC, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Bicycle Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings BDRXBiodexa Pharmaceuticals PLC1 0 0 BCYCBicycle Therapeutics PLC4 3 0 -
Is BDRX or BCYC More Risky?
Biodexa Pharmaceuticals PLC has a beta of 1.705, which suggesting that the stock is 70.482% more volatile than S&P 500. In comparison Bicycle Therapeutics PLC has a beta of 1.398, suggesting its more volatile than the S&P 500 by 39.825%.
-
Which is a Better Dividend Stock BDRX or BCYC?
Biodexa Pharmaceuticals PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bicycle Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biodexa Pharmaceuticals PLC pays -- of its earnings as a dividend. Bicycle Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BDRX or BCYC?
Biodexa Pharmaceuticals PLC quarterly revenues are --, which are smaller than Bicycle Therapeutics PLC quarterly revenues of $3.7M. Biodexa Pharmaceuticals PLC's net income of -- is lower than Bicycle Therapeutics PLC's net income of -$51.9M. Notably, Biodexa Pharmaceuticals PLC's price-to-earnings ratio is -- while Bicycle Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biodexa Pharmaceuticals PLC is 1.11x versus 10.52x for Bicycle Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDRXBiodexa Pharmaceuticals PLC1.11x -- -- -- BCYCBicycle Therapeutics PLC10.52x -- $3.7M -$51.9M
-
Which has Higher Returns BDRX or NCNA?
NuCana PLC has a net margin of -- compared to Biodexa Pharmaceuticals PLC's net margin of --. Biodexa Pharmaceuticals PLC's return on equity of -160.77% beat NuCana PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BDRXBiodexa Pharmaceuticals PLC-- -- $6M NCNANuCana PLC-- -$0.32 -- -
What do Analysts Say About BDRX or NCNA?
Biodexa Pharmaceuticals PLC has a consensus price target of $17.97, signalling upside risk potential of 1183.09%. On the other hand NuCana PLC has an analysts' consensus of $104.00 which suggests that it could grow by 14244.83%. Given that NuCana PLC has higher upside potential than Biodexa Pharmaceuticals PLC, analysts believe NuCana PLC is more attractive than Biodexa Pharmaceuticals PLC.
Company Buy Ratings Hold Ratings Sell Ratings BDRXBiodexa Pharmaceuticals PLC1 0 0 NCNANuCana PLC0 1 0 -
Is BDRX or NCNA More Risky?
Biodexa Pharmaceuticals PLC has a beta of 1.705, which suggesting that the stock is 70.482% more volatile than S&P 500. In comparison NuCana PLC has a beta of 1.464, suggesting its more volatile than the S&P 500 by 46.355%.
-
Which is a Better Dividend Stock BDRX or NCNA?
Biodexa Pharmaceuticals PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biodexa Pharmaceuticals PLC pays -- of its earnings as a dividend. NuCana PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BDRX or NCNA?
Biodexa Pharmaceuticals PLC quarterly revenues are --, which are smaller than NuCana PLC quarterly revenues of --. Biodexa Pharmaceuticals PLC's net income of -- is lower than NuCana PLC's net income of -$836.1K. Notably, Biodexa Pharmaceuticals PLC's price-to-earnings ratio is -- while NuCana PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biodexa Pharmaceuticals PLC is 1.11x versus -- for NuCana PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDRXBiodexa Pharmaceuticals PLC1.11x -- -- -- NCNANuCana PLC-- -- -- -$836.1K
-
Which has Higher Returns BDRX or VRNA?
Verona Pharma PLC has a net margin of -- compared to Biodexa Pharmaceuticals PLC's net margin of -92.29%. Biodexa Pharmaceuticals PLC's return on equity of -160.77% beat Verona Pharma PLC's return on equity of -88.7%.
Company Gross Margin Earnings Per Share Invested Capital BDRXBiodexa Pharmaceuticals PLC-- -- $6M VRNAVerona Pharma PLC94.44% -$0.40 $324.9M -
What do Analysts Say About BDRX or VRNA?
Biodexa Pharmaceuticals PLC has a consensus price target of $17.97, signalling upside risk potential of 1183.09%. On the other hand Verona Pharma PLC has an analysts' consensus of $81.00 which suggests that it could grow by 49.53%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Verona Pharma PLC, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Verona Pharma PLC.
Company Buy Ratings Hold Ratings Sell Ratings BDRXBiodexa Pharmaceuticals PLC1 0 0 VRNAVerona Pharma PLC5 0 0 -
Is BDRX or VRNA More Risky?
Biodexa Pharmaceuticals PLC has a beta of 1.705, which suggesting that the stock is 70.482% more volatile than S&P 500. In comparison Verona Pharma PLC has a beta of 0.165, suggesting its less volatile than the S&P 500 by 83.527%.
-
Which is a Better Dividend Stock BDRX or VRNA?
Biodexa Pharmaceuticals PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verona Pharma PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biodexa Pharmaceuticals PLC pays -- of its earnings as a dividend. Verona Pharma PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BDRX or VRNA?
Biodexa Pharmaceuticals PLC quarterly revenues are --, which are smaller than Verona Pharma PLC quarterly revenues of $36.7M. Biodexa Pharmaceuticals PLC's net income of -- is lower than Verona Pharma PLC's net income of -$33.8M. Notably, Biodexa Pharmaceuticals PLC's price-to-earnings ratio is -- while Verona Pharma PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biodexa Pharmaceuticals PLC is 1.11x versus -- for Verona Pharma PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BDRXBiodexa Pharmaceuticals PLC1.11x -- -- -- VRNAVerona Pharma PLC-- -- $36.7M -$33.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Down 50%, Is Dell Technologies a Buy?
Dell (NYSE:DELL)’s share price has been on a roller coaster…
How Bad Will the Stock Market Get?
In recent trading days, global stock markets have seen massive…
Stock Ideas
Sell
36
Is MSFT Stock a Buy?
Market Cap: $2.6T
P/E Ratio: 30x
Sell
30
Is AAPL Stock a Buy?
Market Cap: $2.6T
P/E Ratio: 28x
Sell
33
Is NVDA Stock a Buy?
Market Cap: $2.3T
P/E Ratio: 33x
Alerts
Buy
55
SLNO alert for Apr 9
Soleno Therapeutics [SLNO] is up 7.3% over the past day.
Sell
20
HELE alert for Apr 9
Helen Of Troy [HELE] is up 10.1% over the past day.
Sell
18
OXM alert for Apr 9
Oxford Industries [OXM] is up 17.72% over the past day.
